Atlas Trials

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Clinical trial NCT06220318 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06220318
Sponsor
Fujian Haixi Pharmaceuticals Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Solid Tumor
Start date
2023-07-19
Primary completion
2026-08-30
Enrollment
155

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.